

Full Reference	Cited in Question(s)	Cited on Page(s)
Borgerding, M. F., Bodnar, J. A., Curtin, G. M., & Swauger, J. E. (2012). The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. <i>Regulatory Toxicology and Pharmacology</i> , 64(3), 367-387. doi:10.1016/j.yrtph.2012.09.003	8	41, 42
Borgida, E., Loken, B., Williams, A. L., Vitriol, J., Stepanov, I., & Hatsukami, D. (2015). Assessing Constituent Levels in Smokeless Tobacco Products: A New Approach to Engaging and Educating the Public. <i>Nicotine Tob Res</i> , 17(11), 1354-1361. doi:10.1093/ntr/ntv007	8	53
Cheng, Y.C., Reyes-Guzman, C.M., Christensen, C.H., Rostron, B.L., Edwards, K.C., Wang, L., . . . van Bommel, D.M. (2020). Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-2014). <i>Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</i> , 29(3), 659-667. doi:10.1158/1055-9965.EPI-19-0766	8	43, 44, 53
CTP.* (2012). Draft Guidance for Industry. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act.	8	45, 46
CTP.* (2019). Memo: Harmful and potentially harmful constituent (HPHC) comparison and evaluation procedure for comparing two tobacco products in the substantial equivalence reports.	8	46
Delnevo, C. D., Hrywna, M., Miller Lo, E. J., & Wackowski, O. A. (2020). Examining market trends in smokeless tobacco sales in the United States: 2011-2019. <i>Nicotine Tob Res</i> . doi:10.1093/ntr/ntaa239	8	41, 45
Fisher, M. T., Tan-Torres, S. M., Gaworski, C. L., Black, R. A., & Sarkar, M. A. (2019). Smokeless tobacco mortality risks: an analysis of two contemporary nationally representative longitudinal mortality studies. <i>Harm Reduct J</i> , 16(1), 27. doi:10.1186/s12954-019-0294-6	8	52

* ALCS does not provide digital copies of web links, readily-available FDA or other government publications, or complete books. The marked item is not provided in the digital archive.

Full Reference	Cited in Question(s)	Cited on Page(s)
Foulds, J., & Ramstrom, L. (2006). Causal effects of smokeless tobacco on mortality in CPS-I and CPS-II? <i>Cancer Causes & Control</i> , 17(2), 227-228. doi:10.1007/s10552-005-0526-9	8	52
Hatsukami, D. K., Jensen, J., Boyle, R., Grillo, M., & Bliss, R. (1999). Characteristics of smokeless tobacco users seeking treatment. <i>Addictive Behaviors</i> , 24(4), 551-557. doi:10.1016/s0306-4603(98)00092-6	8	44
Hatsukami, D., Joseph, A., LeSage, M., Jensen, J., Murphy, S., Pentel, P., . . . Hecht, S. (2007). Developing the science base for reducing tobacco harm. <i>Nicotine and Tobacco Research</i> , 9(SUPPL. 4), 537-553. doi:10.1080/14622200701679040	Introduction	1
Henley, S. J., Thun, M. J., Connell, C., & Calle, E. E. (2005). Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). <i>Cancer Causes & Control</i> , 16(4), 347-358. doi:10.1007/s10552-004-5519-6	8	52, 53
IARC.* (2012). <i>Monographs on the Identification of Carcinogenic Hazards to Humans, No. 100F</i> . Lyon, France: International Agency for Research on Cancer.	8	43
Inoue-Choi, M., Shiels, M. S., McNeel, T. S., Graubard, B. I., Hatsukami, D., & Freedman, N. D. (2019). Contemporary Associations of Exclusive Cigarette, Cigar, Pipe, and Smokeless Tobacco Use With Overall and Cause-Specific Mortality in the United States. <i>JNCI Cancer Spectr</i> , 3(3), pkz036. doi:10.1093/jncics/pkz036	8	40, 52
Marano, Kristin M., Liu, Charlene, Fuller, William, & Gentry, P. Robinan. (2018). Quantitative risk assessment of tobacco products: A potentially useful component of substantial equivalence evaluations. <i>Regulatory toxicology and pharmacology : RTP</i> , 95, 371-384. doi:10.1016/j.yrtph.2018.03.026	8	45, 46, 47
OEHHA.* (1992). Expedited cancer potency values and proposed regulatory levels for certain proposition 65 carcinogens, NNN, CSF (Oral).	8	49
OEHHA.* (2001). Expedited cancer potency values and proposed regulatory levels for certain proposition 65 carcinogens, NNK, CSF (Oral).	8	49, 50

* ALCS does not provide digital copies of web links, readily-available FDA or other government publications, or complete books. The marked item is not provided in the digital archive.

Full Reference	Cited in Question(s)	Cited on Page(s)
OEHHA.* (2009). Appendix B: Chemical-specific summaries of the Information used to derive unit risk and cancer potency values, Formaldehyde, CSF (Oral).	8	49
Prasad, G. L., Jones, B. A., Chen, P., & Gregg, E. O. (2016). A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers. <i>Clinical Chemistry and Laboratory Medicine</i> , 54(4), 633-642. doi:10.1515/cclm-2015-0594	8	44
Rodu, Brad, & Cole, Philip. (2002). Smokeless tobacco use and cancer of the upper respiratory tract. <i>Oral surgery</i> , 93(5), 511-515. doi:10.1067/moe.2002.123497	8	52
Rodu, Brad, & Cole, Philip. (2009). Lung cancer mortality: comparing Sweden with other countries in the European Union. <i>Scandinavian Journal of Public Health</i> , 37(5), 481-486. doi:10.1177/1403494809105797	8	52
Rostron, B. L., Chang, C. M., van Bemmelen, D. M., Xia, Y., & Blount, B. C. (2015). Nicotine and Toxicant Exposure among U.S. Smokeless Tobacco Users: Results from 1999 to 2012 National Health and Nutrition Examination Survey Data. <i>Cancer Epidemiology, Biomarkers & Prevention</i> , 24(12), 1829-1837. doi:10.1158/1055-9965.Epi-15-0376	8	44
Stepanov, I., Jensen, J., Hatsukami, D., & Hecht, S. S. (2008). New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. <i>Nicotine Tob Res</i> , 10(12), 1773-1782. doi:10.1080/14622200802443544	8	41, 42
Suwazono, Y., Kido, T., Nakagawa, H., Nishijo, M., Honda, R., Kobayashi, E., . . . Nogawa, K. (2009). Biological half-life of cadmium in the urine of inhabitants after cessation of cadmium exposure. <i>Biomarkers</i> , 14(2), 77-81. doi:10.1080/13547500902730698	8	43
TCEQ.* (2009). TRRP protective concentration levels, Table 4—Combined tier 1 soil PCLs, residential.	8	48, 49
Timberlake, D. S., Nikitin, D., Johnson, N. J., & Altekruse, S. F. (2017). A longitudinal study of smokeless tobacco use and mortality in the United States. <i>International Journal of Cancer</i> , 141(2), 264-270. doi:10.1002/ijc.30736	8	52, 55

* ALCS does not provide digital copies of web links, readily-available FDA or other government publications, or complete books. The marked item is not provided in the digital archive.

Full Reference	Cited in Question(s)	Cited on Page(s)
Tomar, S.L. (2019). The Transnational Tobacco Industry and Oral Health. <i>Community Dental Health</i> , 36(2), 163-168. doi:10.1922/CDH_SpecialIssueTomar06	8	41, 45
U.S. EPA.* (1989a). Integrated Risk Information System, Cadmium, RfD.	8	45, 47, 49, 50
U.S. EPA.* (1989b). US Environmental Protection Agency, USEPA, 1989. Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part a). Retrieved from https://www.epa.gov/sites/production/files/2015-09/documents/rags_a.pdf	8	45, 47
U.S. EPA.* (1990). Integrated Risk Information System, Formaldehyde, RfD.	8	45, 49, 50
U.S. EPA.* (1991a). Integrated Risk Information System, Arsenic, RfD.	8	45, 49, 50
U.S. EPA.* (1991b). Provisional Peer Reviewed Toxicity Values, Crotonaldehyde, RfD.	8	49
U.S. EPA.* (1995). Integrated Risk Information System, Arsenic, CSF (Oral).	8	49, 50
U.S. EPA.* (1997a). Exposure Factors Handbook.	8	47
U.S. EPA.* (1997b). Health Effects Assessment Summary Tables - Crotonaldehyde, CSF (Oral).	8	49, 50
U.S. EPA.* (2002). Guidance on Cumulative Risk Assessment of Pesticide Chemicals that Have a Common Mechanism of Toxicity. iv.	8	45

* ALCS does not provide digital copies of web links, readily-available FDA or other government publications, or complete books. The marked item is not provided in the digital archive.

Full Reference	Cited in Question(s)	Cited on Page(s)
U.S. EPA.* (2009a). Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part f).	8	45
U.S. EPA.* (2009b). US Environmental Protection Agency, Risk Assessment Guidance for Superfund Volume 1 Human Health Evaluation Manual (Part f). Retrieved from https://www.epa.gov/sites/production/files/2015-09/documents/partf_200901_final.pdf	8	47
U.S. EPA.* (2014). US Environmental Protection Agency, Office of Solid Waste and Emergency Response Directive 9200.1-120. Memorandum, Human Health Evaluation Manual, Supplemental Guidance, Update of Standard Default Exposure Factors. Retrieved from https://epa-prgs.ornl.gov/chemicals/help/documents/OSWER_Directive_corrected.pdf	8	45, 47
U.S. EPA.* (2017a). Integrated Risk Information System, Benzo[a]pyrene, CSF, RfD (Oral).	8	47, 49, 50
U.S. EPA.* (2017b). Tobacco Product Standard for N-nitrosonornicotine Level in Finished Smokeless Tobacco - Proposed Rule.	8	47
Xu, X., Fiacco, L., Rostron, B., Homsy, G., Salazar, E., Levine, B., . . . Nonnemaker, J. (2021). Assessing quality-adjusted years of life lost associated with exclusive cigarette smoking and smokeless tobacco use. <i>Preventive Medicine</i> , 150, 106707. doi:10.1016/j.ypmed.2021.106707	8	40
Zeller, M., & Hatsukami, D. (2009). The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. <i>Tobacco Control</i> , 18(4), 324-332. doi:10.1136/tc.2008.027318	Introduction	1

* ALCS does not provide digital copies of web links, readily-available FDA or other government publications, or complete books. The marked item is not provided in the digital archive.